HT-29 is a human colorectal adenocarcinoma cell line with epithelial morphology. These cells are sensitive to the chemotherapeutic drugs 5-fluorouracil and oxaliplatin, which are standard treatment options for colorectal cancer. In addition to being a xenograft tumor model for colorectal cancer, the HT-29 cell line is also used as an in-vitro model to study absorption, transport, and secretion by intestinal cells. Under standard culture conditions, these cells grow as a nonpolarized, undifferentiated multilayer. Altering culture conditions or treating the cells with various inducers, however, results in a differentiated and polarized morphology, characterized by the redistribution of membrane antigens and development of an apical brush-border membrane.
This cell line was established in 1964 from the primary tumor of a 44-year-old Caucasian female with colorectal adenocarcinoma.
Jorgen Fogh, PhD, formerly at Sloan Kettering Institute, Memorial Sloan Kettering
- Fogh J et al. (1977) One hundred and twenty-seven cultured human tumor cell lines producing tumors in nude mice. Journal of the National Cancer Institute 59: 221-226 (PubMed ID: 327080)
- Cohen E at al. (1999) Induced differentiation in HT29, a human colon adenocarcinoma cell line. Journal of Cell Science 112: 2657-2666 (PubMed ID: 10413674)
- Nautiyal J et al. (2011) Combination of dasatinib and curcumin eliminates chemo-resistant colon cancer cells. Journal of Molecular Signaling 6: 7 (PubMed ID: 21774804)
This cell line may be licensed nonexclusively for research or commercial purposes.
For internal research purposes by a commercial entity: Utilize MSK’s Express License, available here. In order to streamline and expedite the licensing of select MSK cell lines, the terms of this non-exclusive license are non-negotiable. Please note: This license is only available for select cell lines, including this one.
To proceed, please download this contract, fill in all relevant fields, and email a scanned version to Alexandra Buga at email@example.com. Once this license has been executed by MSK, you will receive a signed copy and invoice, and can then place your order with ATCC.
For non-licensing requests from academic-research institutions: Contact Frances Weis-Garcia, PhD, Associate Laboratory Member/Head, Antibody & Bioresource Core Facility, MSK, 646-888-2354, firstname.lastname@example.org.